The efficacy and the utility of switching into glucagon like peptide-1 receptor agonist plus basal insulin therapy in type 2 diabetic patients treated with Basal-Bolus therapy.

The efficacy and the utility of switching into glucagon like peptide-1 receptor agonist plus basal insulin therapy in type 2 diabetic patients treated with Basal-Bolus therapy. - The efficacy and the utility of switching from basal-bolus therapy to GLP-1 RA plus basal insulin therapy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032665

Enrollment

100

Registered

2018-05-21

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Change from prandial insulins to liraglutide Change from liraglutide to duraglutide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes. The value of HbA1c less than 7.0% with basal-bolus insulin therapy without any oral anti-diabetics. Sum of prandial insulin dose less than 24 units

Exclusion criteria

Exclusion criteria: Type 1 diabetes with severe liver disease, severe renal disease or severe heart disease with any carcinoma under pregnancy

Design outcomes

Primary

Measure	Time frame
the characteristics of the patient who can successfully switch the treatment efficacy(Diabetes treatment satisfaction questionnaire: DTSQ)	—

Secondary

Measure	Time frame
glycemic control(continuous glucose monitoring) Urinary albumin concentration, Urinary L-FABP concentration	—

Countries

Japan

Contacts

Public ContactFumitaka Okajima

Nippon Medical School Chiba-Hokusoh Hospital Department of Endocrinology

okaji@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026